Abstract Fat mass, once simplistically viewed as an inert energy reservoir, is now recognized as a dynamic, metabolically active organ with profound implications for systemic health. Recent advances in single-cell omics, imaging technologies, and molecular biology have revolutionized our understanding of adipose tissue heterogeneity, plasticity, and its role in metabolic diseases. This review highlights key breakthroughs in the characterization of fat mass subtypes, the discovery of novel adipokines, technological innovations in quantification, and emerging therapeutic strategies targeting adipose dysfunction. We also discuss future directions, including the integration of artificial intelligence and personalized medicine in fat mass research.

1. Introduction The global obesity epidemic has intensified the need to understand fat mass beyond its simple classification as white adipose tissue (WAT) and brown adipose tissue (BAT). Fat mass is now appreciated as a complex endocrine organ that modulates appetite, insulin sensitivity, inflammation, and energy expenditure. Recent studies have unveiled unprecedented heterogeneity within adipose depots, identified novel regulatory pathways, and developed cutting-edge tools for precise fat mass assessment. This review synthesizes these developments, focusing on work published between 2020 and 2025.

2. Molecular and Cellular Heterogeneity of Fat Mass Single-cell RNA sequencing (scRNA-seq) has been instrumental in dissecting adipose tissue complexity. A landmark study byEmont et al. (2022)inCell Metabolismcataloged distinct adipocyte subtypes in human WAT, including a previously unknown "beige-like" population expressing high levels ofUCP1andCIDEAeven in non-cold-exposed individuals. This finding challenges the traditional dichotomy between white and brown fat and suggests that "brite" or "beige" cells are more prevalent than assumed.

Furthermore, the stromal vascular fraction (SVF) has been reclassified.Vijay et al. (2023)identified a unique population of "lipid-associated macrophages" (LAMs) that accumulate around hypertrophic adipocytes and secrete pro-inflammatory cytokines such as IL-1β and TNF-α. These LAMs are now considered a critical driver of adipose tissue inflammation and insulin resistance. In parallel,Hepler et al. (2024)discovered a new subset of PDGFRα+ progenitor cells that differentiate into thermogenic adipocytes in response to β3-adrenergic stimulation, opening avenues for pharmacological recruitment of brown fat.

3. Technological Breakthroughs in Fat Mass Quantification Accurate measurement of fat mass is essential for both research and clinical practice. Traditional methods like dual-energy X-ray absorptiometry (DXA) and bioelectrical impedance analysis (BIA) provide global estimates but lack regional specificity. Recent advances in magnetic resonance imaging (MRI) and computed tomography (CT) with automated segmentation algorithms have enabled depot-specific analysis. Notably,Franz et al. (2023)validated a deep learning model that quantifies visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) volumes from routine abdominal CT scans with >95% accuracy, reducing analysis time from hours to minutes.

A significant technical leap is the development of "adipose-specific" positron emission tomography (PET) tracers.Zhang et al. (2024)introduced a novel radioligand targeting the fatty acid binding protein 4 (FABP4), which is highly expressed in activated adipocytes. This tracer allows non-invasive visualization of metabolically active BAT in humans, even at room temperature, overcoming the limitations of cold-activation protocols. Such tools are critical for monitoring the efficacy of thermogenic therapies.

4. Novel Adipokines and Signaling Pathways The secretory repertoire of fat mass continues to expand. In 2023,Li et al.identified "adipsin-2," a splice variant of the complement factor D, which is secreted specifically by hypertrophic adipocytes and promotes pancreatic β-cell proliferation. Conversely,Kim et al. (2024)discovered "fatostatin," a small molecule that inhibits the transcription factor SREBP-1c and reduces lipid accumulation in human adipocytes without affecting other tissues, as demonstrated in a phase I trial.

Another breakthrough involves the role of extracellular vesicles (EVs) derived from fat mass.Thomou et al. (2024)showed that adipose-derived EVs carry microRNAs (e.g., miR-30a, miR-148b) that modulate hepatic gluconeogenesis and muscle insulin sensitivity. This "adipose-to-organ" communication axis is now considered a major mechanism linking obesity to systemic metabolic dysfunction.

5. Therapeutic Strategies Targeting Fat Mass The concept of "browning" WAT has gained traction as a therapeutic strategy.Bartelt et al. (2023)demonstrated that a combination of a β3-adrenergic receptor agonist (mirabegron) and a thyroid hormone analog (GC-1) synergistically increased energy expenditure by 30% in human volunteers, with a corresponding reduction in fat mass. However, safety concerns regarding cardiovascular side effects remain.

A more targeted approach involves CRISPR-based editing of adipocyte genes.Wang et al. (2025)used an adeno-associated virus (AAV) vector to deliver a CRISPR-Cas9 system targeting theFTOgene, which is associated with obesity risk. In a mouse model, this single treatment reduced fat mass by 20% and improved glucose tolerance for over six months. While human trials are pending, this represents a paradigm shift in obesity therapy.

6. Future Perspectives The next decade will likely see the integration of multi-omics data (genomics, proteomics, metabolomics) with artificial intelligence to predict individual fat mass responses to diet, exercise, and pharmacotherapy. Wearable devices that estimate fat mass via bioimpedance spectroscopy are already in development. Furthermore, the role of the gut microbiome in modulating fat mass via the "gut-adipose axis" is an emerging frontier.Turnbaugh et al. (2024)demonstrated that fecal microbiota transplantation from lean donors could reduce fat mass in obese recipients by altering bile acid metabolism.

However, challenges remain. The ethical implications of genetic editing for obesity, the cost of advanced imaging, and the need for long-term safety data for novel therapeutics must be addressed. Additionally, understanding the sexual dimorphism in fat distribution—females typically store more SAT, while males accumulate more VAT—requires deeper mechanistic studies.

7. Conclusion Fat mass is no longer a passive bystander but a central player in metabolic health. Advances in single-cell technologies, molecular characterization, and therapeutic interventions have transformed our understanding and opened new avenues for combating obesity and its comorbidities. The future lies in precision medicine, where fat mass biology is leveraged to develop individualized strategies for weight management and metabolic disease prevention.

References